Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$11.65 - $22.07 $587,136 - $1.11 Million
-50,398 Reduced 50.4%
49,602 $961,000
Q3 2020

Nov 16, 2020

BUY
$8.96 - $14.12 $896,000 - $1.41 Million
100,000 New
100,000 $1.12 Million

Others Institutions Holding SPRO

About Spero Therapeutics, Inc.


  • Ticker SPRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,067,500
  • Market Cap $33.3M
  • Description
  • Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...
More about SPRO
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.